ERBB2 and breast cancer: Luminal B breast cancer shows more aggressive phenotypes than luminal A breast cancer and higher insensitivity to neoadjuvant chemotherapy than basal-like and HER2+ breast cancers, leading to its obstinacy and poor prognosis of patients [2, 4].